You are not currently logged in.
Access JSTOR through your library or other institution:
If You Use a Screen ReaderThis content is available through Read Online (Free) program, which relies on page scans. Since scans are not currently available to screen readers, please contact JSTOR User Support for access. We'll provide a PDF copy for your screen reader.
A Universal Vaccine for Serogroup B Meningococcus
Marzia M. Giuliani, Jeannette Adu-Bobie, Maurizio Comanducci, Beatrice Aricò, Silvana Savino, Laura Santini, Brunella Brunelli, Stefania Bambini, Alessia Biolchi, Barbara Capecchi, Elena Cartocci, Laura Ciucchi, Federica Di Marcello, Francesca Ferlicca, Barbara Galli, Enrico Luzzi, Vega Masignani, Davide Serruto, Daniele Veggi, Mario Contorni, Maurizio Morandi, Alessandro Bartalesi, Vanda Cinotti, Donatella Mannucci, Francesca Titta, Elisa Ovidi, Jo Anne Welsch, Dan Granoff, Rino Rappuoli and Mariagrazia Pizza
Proceedings of the National Academy of Sciences of the United States of America
Vol. 103, No. 29 (Jul. 18, 2006), pp. 10834-10839
Published by: National Academy of Sciences
Stable URL: http://www.jstor.org/stable/30049368
Page Count: 6
You can always find the topics here!Topics: Vaccination, Antigens, Aluminum, Hydroxides, Antibodies, Epidemiology, Infants, Neisseria meningitidis, Oligonucleotides, Immunity
Were these topics helpful?See something inaccurate? Let us know!
Select the topics that are inaccurate.
Since scans are not currently available to screen readers, please contact JSTOR User Support for access. We'll provide a PDF copy for your screen reader.
Preview not available
Meningitis and sepsis caused by serogroup B meningococcus are two severe diseases that still cause significant mortality. To date there is no universal vaccine that prevents these diseases. In this work, five antigens discovered by reverse vaccinology were expressed in a form suitable for large-scale manufacturing and formulated with adjuvants suitable for human use. The vaccine adjuvanted by aluminum hydroxide induced bactericidal antibodies in mice against 78% of a panel of 85 meningococcal strains representative of the global population diversity. The strain coverage could be increased to 90% and above by the addition of CpG oligonucleotides or by using MF59 as adjuvant. The vaccine has the potential to conquer one of the most devastating diseases of childhood.
Proceedings of the National Academy of Sciences of the United States of America © 2006 National Academy of Sciences